Mentions in press and media 11
| Date | Title | Description |
| 12.11.2025 | Modulight Biotherapeutics Raises $12M in Seed Funding | Modulight Biotherapeutics, a Boston, MA-based developer of novel optogenetic platform for the treatment of neurological disorders, raised $12.2M in Seed funding. The round was led by Jibe Ventures and LocalGlobe, with participation from Nex... |
| 12.11.2025 | Modulight Biotherapeutics: $12.2 Million Seed Round Raised To Pioneer Light-Based Therapies For Neurological Disorders | Modulight Biotherapeutics announced the closing of its $12.2 million Seed funding round to accelerate the development of its novel optogenetic therapy platform targeting neurological disorders. The round was led by Jibe Ventures and LocalGl... |
| 29.05.2025 | Kyron.bio: Pioneering a New Era in Antibody Therapeutics | In the bustling world of biotechnology, a new player is making waves. Kyron.bio, a Paris-based startup, has secured €5.5 million in seed funding to revolutionize drug development. This funding is not just a financial boost; it’s a lifeline ... |
| 29.05.2025 | Kyron.bio Raises €5.5M in Funding | Kyron.bio, a Paris, France-based glycan engineering startup, raised €5.5m in funding. The round was led by HCVC with participaiton from Verve Ventures, Entrepreneur First, and Saras Capital. The company intends to use the funds to expand op... |
| 28.05.2025 | Paris-based kyron.bio secures €5.5 million to tackle drug efficiency and safety | French BioTech company kyron.bio announced today a €5.5 million Seed funding round to tackle the issues of varying efficacy and dangerous side effects in current drug development, using control of sugar molecules – also known as glycans. Th... |
| 28.05.2025 | Kyron.bio Secures $6.2M to Optimize Biologic Drug Development with Precision Glycan Engineering | What You Should Know: – Biotechnology company kyron.bio announced the successful closing of a $6.2M (€5.5M) seed funding round aimed at solving critical challenges in biologic drug development, specifically varying efficacy and the dangers ... |
| 28.05.2025 | Kyron.bio raises €5.5M to transform antibody design | One of the biggest challenges facing biologic drug developers are varying efficacy and the dangers of side effects. Biotechnology company Kyron.bio has raised €5.5 million funding to solve these issues using precise control of sugar molecul... |
| 08.11.2024 | Infinitopes: Pioneering the Future of Cancer Vaccines | In the world of cancer treatment, hope often feels like a flickering candle in a storm. Yet, a new player is emerging, determined to turn that flicker into a blazing beacon. Infinitopes, a biotech company born from the halls of Oxford Unive... |
| 08.11.2024 | The Future of Vision and Immunotherapy: Innovations from AllFocal Optics and Infinitopes | In the world of technology and healthcare, two companies are pushing boundaries. AllFocal Optics and Infinitopes are not just making waves; they are creating tsunamis of innovation. Each is tackling a unique challenge: enhancing human visio... |
| 08.11.2024 | Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial | Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line patients with surgically rese... |
Show more